Advertisement

Psychopharmacology

, Volume 168, Issue 4, pp 465–474 | Cite as

Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes

  • Iain S. McGregor
  • Clint G. Gurtman
  • Kirsten C. Morley
  • Kelly J. Clemens
  • Arjan Blokland
  • Kong M. Li
  • Jennifer L. Cornish
  • Glenn E. Hunt
Original Investigation

Abstract

Rationale

There is some uncertainty whether the acute hyperthermia caused by MDMA (ecstasy) plays a significant role in determining the long-term neurotoxic effects on brain 5-HT systems and associated changes in mood and behaviour.

Objective

The present study assessed whether long-term behavioural and cognitive changes seen in MDMA-treated rats are affected by hyperthermia at the time of drug administration.

Method

Male Wistar rats were treated with MDMA (4×5 mg/kg i.p. over 4 h on 2 consecutive days) or vehicle at either a high ambient temperature (28°C) or a low ambient temperature (16°C). Eight to 18 weeks later, rats were tested in behavioural measures of anxiety (social interaction and emergence tests), a test of cognition (object recognition test) and the forced swim test of depression. At the conclusion of behavioural testing the rats were killed and their brains analysed using HPLC.

Results

MDMA treatment caused a clear and consistent hyperthermia at 28°C and hypothermia at 16°C. Months later, rats pre-treated with MDMA at either 16 or 28°C displayed increased anxiety in the social interaction and emergence tests and reduced escape attempts and increased immobility in the forced swim test. MDMA pre-treatment was also associated with poorer memory on the object recognition test, but only in rats given the drug at 28°C. Rats pre-treated with MDMA showed loss of 5-HT in the hippocampus, striatum, amygdala and cortex, regardless of body temperature at the time of dosing. However, 5-HIAA loss in the amygdala and hippocampus was greater in rats pre-treated at 28°C. Dopamine in the striatum was also depleted in rats given MDMA.

Conclusions

These results indicate that hyperthermia at the time of dosing with MDMA is not necessary to produce subsequent 5-HT depletion and anxiety in rats. They also extend previous findings of long-term effects of brief exposure to MDMA in rats to include apparent "depressive" symptoms in the forced swim model.

Keywords

MDMA Ecstasy Anxiety Depression Serotonin 5-HT Temperature 

Notes

Acknowledgements

This work was supported by an NH&MRC grant to Iain S. McGregor and Glenn E. Hunt. We are grateful to Geoffrey van der Plasse for technical assistance and to Darek Figa and Debbie Brookes for animal care.

References

  1. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB (1987) 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242:911–916PubMedGoogle Scholar
  2. Blokland A, Lieben C, Deutz NEP (2002) Anxiogenic and depressive-like effects, but no cognitive deficits, after repeated moderate tryptophan depletion in the rat. J Psychopharmacol 16:39–49PubMedGoogle Scholar
  3. Boot BP, McGregor LS, Hall W (2000) MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 355:1818–1821CrossRefPubMedGoogle Scholar
  4. Bowyer JF, Tank AW, Newport GD, Slikker W Jr, Ali SF, Holson RR (1992) The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 260:817–824Google Scholar
  5. Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W Jr, Holson RR (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 268:1571–1580Google Scholar
  6. Bowyer JF, Holson RR, Miller DB, O'Callaghan JP (2001) Phenobarbital and dizocilpine can block methamphetamine-induced neurotoxicity in mice by mechanisms that are independent of thermoregulation. Brain Res 919:179–183CrossRefPubMedGoogle Scholar
  7. Broening HW, Bowyer JF, Slikker W (1995) Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (±)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther 275:325–333PubMedGoogle Scholar
  8. Callahan BT, Cord BJ, Ricaurte GA (2001) Long-term impairment of anterograde axonal transport along fiber projection originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40:113–121CrossRefPubMedGoogle Scholar
  9. Chadwick IS, Curry PD, Linsley A, Freemont AJ, Doran B (1991) Ecstasy, 3-4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med 84:371PubMedGoogle Scholar
  10. Colado MI, Murray TK, Green AR (1993) 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol 108:583–589PubMedGoogle Scholar
  11. Colado MI, Williams JL, Green AR (1995) The hyperthermic and neurotoxic effects of "Ecstasy" (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115:1281–1289PubMedGoogle Scholar
  12. Colado MI, Granados R, Oshea E, Esteban B, Green AR (1998) Role of hyperthermia in the protective action of clomethiazole against MDMA (Ecstasy)-induced neurodegeneration, comparison with the novel nmda channel blocker AR-R15896AR. Br J Pharmacol 124:479–484PubMedGoogle Scholar
  13. Colado MI, O'Shea E, Esteban B, Granados R, Green AR (1999) In vivo evidence against clomethiazole being neuroprotective against MDMA ("Ecstasy")-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism. Neuropharmacology 38:307–314CrossRefPubMedGoogle Scholar
  14. Colado MI, O'Shea E, Esteban B, Green AR (2001) Studies on the neuroprotective effect of the enantiomers of AR-A008055, a compound structurally related to clomethiazole, on MDMA ("Ecstasy")-induced neurodegeneration in rat brain. Psychopharmacology 157:82–88CrossRefPubMedGoogle Scholar
  15. Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23:238–245CrossRefPubMedGoogle Scholar
  16. Dafters RI (1994) Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in rats. Psychopharmacology 114:505–508Google Scholar
  17. Dafters RI (1995) Hyperthermia following MDMA administration in rats—effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav 58:877–882PubMedGoogle Scholar
  18. Farfel GM, Seiden LS (1995) Role of hypothermia in the mechanism of protection against serotonergic toxicity.1. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 9755 and NBQX. J Pharmacol Exp Ther 272:860–867PubMedGoogle Scholar
  19. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G (1995) Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). J Neurosci 15:5476–5485PubMedGoogle Scholar
  20. Gordon CJ, Watkinson WP, O'Callaghan JP, Miller DB (1991) Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 38:339–344PubMedGoogle Scholar
  21. Green AR, McGregor IS (2002) On the long-term increase in anxiety following central serotonin depletion with MDMA ("Ecstasy"). Psychopharmacology 162:448–450Google Scholar
  22. Green AR, Cross AJ, Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy). Psychopharmacology 119:247–260PubMedGoogle Scholar
  23. Gurtman CG, Morley KC, Li KM, Hunt GE, McGregor IS (2002) Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. Eur J Pharmacol 446:89–96CrossRefPubMedGoogle Scholar
  24. Harkin A, Connor TJ, Mulrooney J, Kelly JP, Leonard BE (2001) Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats. Life Sci 68:1367–1382CrossRefPubMedGoogle Scholar
  25. Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("Ecstasy"). Lancet 340:384–387PubMedGoogle Scholar
  26. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000) Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23:396–404CrossRefPubMedGoogle Scholar
  27. Malberg JE, Seiden LS (1997) Administration of fenfluramine at different ambient temperatures produces different core temperature and 5-HT neurotoxicity profiles. Brain Res 765:101–107CrossRefPubMedGoogle Scholar
  28. Malberg JE, Seiden LS (1998) Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18:5086–5094PubMedGoogle Scholar
  29. Malberg JE, Sabol KE, Seiden LS (1996) Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 278:258–267PubMedGoogle Scholar
  30. Mallick A, Bodenham AR (1997) MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. J Accident Emer Med 14:336–338Google Scholar
  31. Marston HM, Reid ME, Lawrence JA, Olverman HJ, Butcher SP (1999) Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. Psychopharmacology 144:67–76Google Scholar
  32. Matuszewich L, Filon ME, Finn DA, Yamamoto BK (2002) Altered forebrain neurotransmitter responses to immobilization stress following 3,4-methylenedioxymethamphetamine. Neuroscience 110:41–48CrossRefPubMedGoogle Scholar
  33. Mechan AO, Moran PM, Elliott JM, Young AMJ, Joseph MH, Green AR (2002) A study of the effects of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) on the subsequent long-term behaviour of rats in the plus maze and open field. Psychopharmacology 159:167–175PubMedGoogle Scholar
  34. Morgan MJ (2000) Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152:230–248PubMedGoogle Scholar
  35. Morley KC, Gallate JE, Hunt GE, Mallet PE, McGregor IS (2001) Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("Ecstasy"). Eur J Pharmacol 433:91–99PubMedGoogle Scholar
  36. O'Loinsigh ED, Boland G, Kelly JP, O'Boyle KM (2001) Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. Prog Neuro-Psychopharmacol Biol Psychiatry 25:621–638Google Scholar
  37. O'Shea E, Granados R, Esteban B, Colado MI, Green AR (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (Ecstasy). Neuropharmacology 37:919–926CrossRefPubMedGoogle Scholar
  38. Parrott AC (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 16:557–577Google Scholar
  39. Parrott AC (2002) Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837–844CrossRefPubMedGoogle Scholar
  40. Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition—before, during and after a Saturday night dance. Psychopharmacology 139:261–268CrossRefPubMedGoogle Scholar
  41. Prickaerts J, van Staveren WCG, Sik A, Markerink-van Ittersum M, Niewohner U, van der Staay FJ, Blokland A, de Vente J (2002) Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 113:351–361CrossRefPubMedGoogle Scholar
  42. Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C (1985) Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229:986–988PubMedGoogle Scholar
  43. Ricaurte GA, McCann UD, Szabo Z, Scheffel U (2000) Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Toxicol Lett 112:143–146CrossRefGoogle Scholar
  44. Ricaurte G, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2002) Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("Ecstasy"). Science 297: 2260–2263CrossRefPubMedGoogle Scholar
  45. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA (1993) Serotonergic recovery after (±)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J Pharmacol Exp Ther 264:1484–1491Google Scholar
  46. Schifano F (2000) Potential human neurotoxicity of MDMA ("Ecstasy"): Subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsychobiology 42:25–33PubMedGoogle Scholar
  47. Schifano F, Difuria L, Forza C, Minicuci N, Bricolo R (1998) MDMA (Ecstasy) consumption in the context of polydrug abuse—a report on 150 patients. Drug Alcohol Depend 52:85–90PubMedGoogle Scholar
  48. Schmidt CJ, Black CK, Abbate GM, Taylor VL (1990) Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res 529:85–90PubMedGoogle Scholar
  49. Schworer H, Racke K, Kilbinger H (1987) Cholinergic modulation of the release of 5-hydroxytryptamine from the guinea pig ileum. Naunyn-Schmiedeberg's Arch Pharmacol 336:127–132Google Scholar
  50. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999) Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55:105–115PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Iain S. McGregor
    • 1
  • Clint G. Gurtman
    • 1
  • Kirsten C. Morley
    • 1
  • Kelly J. Clemens
    • 1
  • Arjan Blokland
    • 2
  • Kong M. Li
    • 3
  • Jennifer L. Cornish
    • 1
  • Glenn E. Hunt
    • 4
  1. 1.School of PsychologyUniversity of SydneySydneyAustralia
  2. 2.Department of PsychologyUniversity of MaastrichtMaastrichtThe Netherlands
  3. 3.Department of PharmacologyUniversity of SydneySydneyAustralia
  4. 4.Department of Psychological MedicineUniversity of Sydney, Concord HospitalSydneyAustralia

Personalised recommendations